WCN26-3956 SUCCESSFUL TREATMENT OF LUPUS NEPHRITIS BY SWITCHING FROM BELIMUMAB TO TELITACICEPT: A CASE ANALYSIS

Read full text Summarise with VIRAT
Authors: Jia Lv, Xuehong Lu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Telitacicept is a novel recombinant fusion protein composed of the extracellular soluble portion of TACI and the Fc fragment of human IgG. It can bind to both B-lymphocyte stimulator (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), thereby dually targeting and inhibiting B cell-mediated autoimmune responses. This paper reports a case of a patient who showed ineffective response to one year of belimumab treatment but achieved effective outcomes after switching to telitacicept combined with standard therapy.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105737–105737
Publication date
25 March 2026
Language
EN